Beam Therapeutics
Overview
Beam Named a TIME100 Most Influential Company, TIME100 Industry Leader, & CEO John Evans Recognized on TIME100 Health List
Base editing is an emerging class of investigational precision genetic medicines designed to overcome the limitations of existing approaches and expand the potential of genetic medicine.
Our delivery strategy is to establish a suite of clinically validated technologies, including electroporation, nonviral and viral delivery modalities.